NCT04767698 - Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

May 10, 2022

Study Completion Date

May 10, 2022

Conditions

Multiple Sclerosis

Interventions

DRUG

Belimumab

200 mg SC weekly for 36 months

DRUG

Short-course Ocrelizumab

300 mg, two infusions two weeks apart and then 600 mg as a single infusion after six months (only one time) (total of two courses of treatment)

DRUG

Continued Ocrelizumab

300 mg, two infusions two weeks apart and then 600 mg as a single infusion every six months for a total of 36 months

Trial Locations (1)

Johns Hopkins University, Baltimore